Skip to main content
PLOS One logoLink to PLOS One
. 2021 Mar 2;16(3):e0248005. doi: 10.1371/journal.pone.0248005

Fine mapping epitope on Glycoprotein-Gn from Severe Fever with Thrombocytopenia Syndrome Virus

Abulimiti Moming 1, Shen Shi 2, Shu Shen 3, Jie Qiao 3, Xihong Yue 2, Bo Wang 3, Juntao Ding 1, Zhihong Hu 3, Fei Deng 3,*, Yujiang Zhang 2,*, Surong Sun 1,*
Editor: Paulo Lee Ho4
PMCID: PMC7924767  PMID: 33651850

Abstract

Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) was recently identified as a tick-borne pathogen that threat to human health. Since 2010, many countries including China, South Korea, and Japan have reported Human SFTS caused by SFTSV infection. The glycoprotein encoded by the SFTSV M gene is the major antigenic component on the viral surface, and responsible for the viral entry, which makes it an important viral antigen and a clinical diagnostic target. The present study aimed to map linear B cell epitopes (BCEs) on the N-terminal glycoprotein (Gn) from SFTSV strain WCH/97/HN/China/2011 using the modified biosynthetic peptide method. Five fine epitopes (E1, 196FSQSEFPD203; E2, 232GHSHKII238; E3, 256VCYKEGTGPC265; E4, 285FCKVAG290, and E5, 316SYGGM320) were identified using the rabbit antisera. Western blot analysis showed that all the five epitopes interacted with the positive serum of sheep that had been naturally infected with SFTSV. Three-dimensional structural modeling analysis showed that all identified BCEs were located on the surface of the SFTSV-Gn and contained flexible loops. The sequence alignment revealed high conservation of the identified BCEs among 13 SFTSV strains from different lineage. These mapped epitopes will escalate the understanding of the epitope distribution and pathogenic mechanism of SFTSV, and could provide a basis for the development of a SFTSV multi-epitope detection antigen.

Introduction

Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) is a human pathogen that causes Severe Fever with Thrombocytopenia Syndrome (SFTS), an emerging disease with high mortality rates up to 30% [1–3]. Since 2010, SFTSV is broadly disseminated in countries like China, South Korea, and Japan [4–6]. The clinical symptoms of SFTSV infections include fever, thrombocytopenia, gastrointestinal disorder, and leukocytopenia [7]. SFTSV is a tick-borne virus [8] and has infected many domestic animals, including goats, cattle, dogs, cats and chickens [9–12]. Humans could generally be infected through tick bites, direct contact with blood or mucus of infected livestock, or patients [13]. Thus, early diagnosis and vaccine development are critical for the prevention and control of SFTSV.

SFTSV is classified as Bandavirus genus within the family Phenuiviridae [14]. The genome consists of three negative stranded RNAs, designated as large (L), medium (M), and small (S), which encode RNA polymerase, glycoprotein (GP) and nucleocapsid protein (NP), respectively. Studies have indicated that GP mediates the first step in the virus replication cycle of binding and entry into the host cell, and are the primary targets for neutralizing antibodies [15, 16]. The GP of Phenuiviridae are synthesized as precursor polyprotein in the infected cells, which can be cleaved by cellular proteases during translation, and processed into the mature virion subunits N-terminal glycoprotein (Gn) and C-terminal glycoprotein (Gc) [17], this step was executed by signal peptidase [18]. Gn/Gc is responsible for cell attachment and membrane fusion, which is required for host cell entry [15]. In the endoplasmic reticulum Gn and Gc are decorated with N-linked glycans, mature Gn and Gc are targeted to the Golgi apparatus for virus budding [19]. Gn and Gc are two major antigenic components on the viral surface, and are incorporated into the envelope of the virus particles. Finally, infected cells released infectious virus particles by exocytosis [17, 20]. Among them, the Gn protein plays a critical role in virion structure formation and adhesion to new target cells, rendering it the main target of neutralizing antibodies [16]. Therefore, elucidating the epitopes or immunodominant regions of Gn is critical for the development of vaccine design and diagnosis of viral infection.

Monoclonal antibodies (mAbs) or convalescent sera from SFTS patients were tested to identify potential therapeutic intervention targets, resulting in the identification of SFTSV-GP as molecules required for host cell entry and also as critical targets for virus neutralization through the development of humoral immunity [21, 22]. Specific treatment with antiviral agents targeting SFTSV is urgently needed to reduce the morbidity and mortality as much as possible. The mAb 10 [21] and mAb 4–5 [23] from SFTS patients targeting SFTSV-Gn were showing successful neutralizing activity to a variety of strains of SFTSV isolates in China [22]. Fine epitope motif mapping is an active field and one of the mapping approaches is called the biosynthetic peptides method (BSP). Overcome many obstacles in other mapping approaches, it has been recognized with many merits including simple design, outstanding cost-efficiency, high reliability, and adaptability to screening the entire region of interest [24]. Some research implies the BSP can be utilized for epitope motif identification [25, 26]. However, there have only been a few reports on epitope identification of SFTSV-Gn.

In this study, to identify immunodominant linear B cell epitopes (BCE) in the Gn (amino acid (aa) 189–451) of SFTSV, named as SGn, the modified BSP method was used to identify the fine epitopes of Gn from the SFTSV strain WCH/97/HN/China/2011 using rabbit polyclonal antibody (pAb) against SFTSV-Gn (α-SGn). We have identified five epitopes on the SGn by using the BSP method. All the five epitopes identified could be recognized by the antisera of sheep infected with SFTSV. We also analyzed the conservation of each epitope among homologous SGn proteins and their location in the predicted three-dimensional (3D) structure. All the five epitopes were distributed on the surface of SGn and thus facilitates antigen-antibody binding accessibility. These investigations have provided novel and comprehensive data about linear BCEs on SFTSV-Gn as well as their unique distribution profile, supported a more solid foundation for the design of SFTSV multi-epitope peptide diagnostics.

Materials and methods

Ethics statement

All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the Committee on the Ethics of Animal Experiments of Xinjiang Key Laboratory of Biological Resources and Genetic Engineering (Approval number: BRGE-AE001), Xinjiang University, and by the Ethics committees of Animal Experiments of Wuhan Institute of Virology, Chinese Academy of Sciences (Approval number: WIVH33201801). This study did not involve suffering or killing the animals.

Plasmids and antibodies

The prokaryotic expression plasmid pMAL-c2x, and SFTSV strain WCH/97/HN/China/2011 were donated by Professor Fei Deng from Wuhan Institute of Virology, Chinese Academy of Sciences. The coding region (aa, 189–451) of SFTSV-Gn from strain WCH/97/HN/China/2011 was amplified by PCR using 2×Rapid Taq Master Mix (Vazyme Biotech, Nanjing, China) according to the manufacture’s instruction. The PCR products were cloned into the plasmid pET-28a to generate the expression plasmid pET-28a-SGn and the insert was confirmed by sequencing. Protein expression and purification were conducted as described [27]. New Zealand rabbits were injected intramuscularly with 0.5 mg of purified SGn segment and immunized at two-week intervals according to the conventional animal immune method. After the third immunization for two weeks, rabbit antiserum was separated and stored at -80°C until use. The sheep serum samples used in the study were kindly provided by Professor Yujiang Zhang from Xinjiang Centers for Disease Control and Prevention (XJCDC). The SFTSV positive or negative sheep serum samples were previously identified using an immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) [27]. SFTSV negative sheep serum and non-immunized New Zealand rabbit serum were used as negative controls in the Western blot and IFA, respectively. Escherichia coli BL21 (TB1 strain) competent cells were used to express 16/8/10mer peptides fused with a truncated MBP protein. Goat anti-rabbit and mouse anti-goat IgG conjugated to horseradish peroxidase (HRP) were purchased from Beijing TransGen Biotech, Co., Ltd. (Beijing, China).

Other reagents and materials

DNA ligase and restriction enzymes BamH I and Sal I (Takara Co., Ltd, Dalian, China), E. coli strain BL21 (TB1) competent cells (Novagen, Inc., Madison, USA), QIA quick Gel Extraction Kit (QIAGEN, Duesseldorf, Germany), 0.2 μm nitrocellulose membrane (Whatman GmbH, Dossel, Germany), unstained or prestained molecular weight markers (ThermoFisher Science, Waltham, MA, USA), and enhanced chemiluminescence (ECL) plus Western blot detection kit (GE Healthcare, Buckinghamshire, UK) were obtained. Other general chemicals were obtained from Shanghai Sangon Co., Ltd (Shanghai, China).

Immunofluorescence Assay (IFA)

Vero cells were infected with SFTSV strain WCH/97/HN/China/2011 at an MOI of 5. At 72 h. p. i., the cells were fixed for 10 min with 4% paraformaldehyde-PBS. Then the fixed cells were incubated in 0.2% Triton X-100-PBS for permeabilization, and then blocked with 5% bovineserum albumin (BSA). The cells were treated with rabbit pAb α-SGn (1:1000 dilution) as a primary antibodies for 2 h at room temperature or 4°C overnight, and incubated with goat anti-rabbit IgG-fluorescein isothiocyanate (FITC) (1:2000 dilution, TransGen Biotech, Beijing, China) for 1 h at room temperature. For visualization of the nuclei, the cells were incubated with Hoechst 33,258 (Beyotime, Shanghai, China) for 5 min at room temperature. All images were acquired using IX73 microscope (Olympus, Tokyo, Japan).

Expression of truncated SGn fragment

In order to map the epitope region of SGn, series of trunctated fragments of SGn were cloned for expression (Fig 1). Primers were synthesized according to the sequence of strain WCH/97/HN/China/2011 (GenBank accession no. JQ341189.1). PCR was performed to amplify the fragments from plasmid pET-28a-SGn which contains the Gn aa 189–461 fragment of SFTSV. The clones were sequenced for verifying the veracity of the fragments. Then, the fragments were sub-cloned into prokaryotic expression vector pET-32a (+) with the BamH I and Hind Ⅲ sites on the 5`and 3`terminus. The expression vectors pET-32a-SGn1, pET-32a-SGn2, pET-32a-SGn3, pET-32a-SGn4 and pET-32a-SGn5 were identified by DNA sequencing (Sangon biotech, Shanghai). The fusion proteins were expressed in E. coli and SDS-PAGE was performed for detecting fusion protein expressions.

Fig 1. Schematic representation of epitope mapping strategy.

Fig 1

(A) Schematic representation of the full length SFTSV-Gn [23], including Signal peptide (SP), three domains (I, red; II, blue; and III, purple), and Transmembrane region (TM). (B) Schematic representation of truncated fragments of Gn. The blue band indicates the SGn (aa 189–451), SGn1 (aa 189–289), SGn 2 (aa 229–319), SGn 3 (aa 269–369), SGn 4 (aa 320–410) and SGn 5 (aa 349–451) segments respectively. (C) Schematic representation of epitope mapping strategy involved 16 overlapping 16mer peptides spanning SGn1 and SGn2.

Mapping strategy and biosynthesis of overlapping 16/8/10mer peptides

To map epitopes on the SGn1 and SGn2 segments, we used the feasible strategy shown in Fig 1. A total of 16 overlapping 16mer peptides spanning Gn numbered P1-P16 were bio-expressed (S1 Table). The 16mers all had an overlap of 8 aa residues between each two adjacent peptides. For fine epitopes motif mapping, eight sets of a total of 42 8mer peptides (named P17-P58) with an overlap of 7 aa residues and 6 10mer peptides (named P59-P64) with an overlap of 9 aa residues were bio-expressed based on the reactive 16mer peptides mapped in the first round of antigenic peptide mapping (S2 Table).

Construction of recombinant plasmids

All plus and minus strands of DNA fragments that encoded target 16/8/10mer peptides and had cohesive end nucleotides of BamH I and TAA-Sal I sites at the 5`- and 3`- ends were synthesized by Tianyi biotech Co., Ltd (Wuhan, China). Each plasmid expressing a 16/8/10mer peptide was constructed into prokaryotic expression vector pMAL-c2x with the Tag protein maltose binding protein (MBP) [28], in which the major steps were conducting an annealing reaction involving paired plus and minus strands, conducting a ligation reaction involving annealed DNA fragment and pMAL-c2x plasmid cut by BamH I and Sal I, then transformed into E. coli (TB1 strain) [29] competent cells with the ligation mixture; screening of the r-clones by carrying out sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using total proteins from each induced clone and observing whether there is a specific 16/8/10mer peptide on the gel; and sequencing of inserted DNA fragment encoding each 16/8/10mer peptide for each determined r-clone to ensure that all synthesized DNA sequences are accurate. The expression vectors were identified by DNA sequencing (Sangon biotech, Shanghai, China).

Expression of target short peptide

Each determined r-clone was used to express a 16/8/10mer peptide in E. coli (TB1 strain) cells, which was fused with the MBP protein, that is, each r-clone was cultivated in 3 mL Luria Bertani (LB) medium with 100 μg/mL ampicillin at 220 rpm overnight. The following day, 30 μL of bacterial culture was added to 3 mL of fresh LB medium, grown at 37°C for 4 h to increase the bacterial density until reaching an optical density at 600 nm (OD600) of 0.5–0.7, IPTG was added to the cultures to a final concentration of 0.2 mM, and then grown at 37°C for 4 h for inducing the expression of the target short peptide. All collected cell pellets containing the expressed 16/8/10mer peptide fusion proteins were stored at -20°C.

SDS-PAGE and Western blot

The cell pellets obtained from 2 mL culture of expressed 16/8/10mer peptide were boiled at 95°C in 200 μL of 1×SDS-PAGE loading buffer for 10 min, and the proteins were resolved by 15% SDS-PAGE under reducing conditions. Gels were either stained with Coomassie brilliant blue G-250 for analyzing the bands corresponding to the target 16/8/10mer peptide, or used for Western blot by electro transferring the proteins onto a 0.2 μm nitrocellulose (NC) membrane [30]. Regarding the specific antigen-antibody reaction, the NC membrane was blocked with 5% (w/v) skimmed milk powder in Tris-buffered saline-Tween 20 (TBS-T), treated with rabbit pAb α-SGn (1:1000 dilution) or sheep serum (1: 100 dilution) as the primary antibody, and then reacted with goat anti-rabbit IgG or mouse anti-goat IgG conjugated to HRP (1:5000 dilution, Trans-Gen Biotech) as the secondary antibody. Finally, the blot was performed using the ECL plus Western blot detection reagent according to the manufacturer’s instructions, and it was then imaged by GE-Image Quant LAS 4000 (GE Healthcare, Buckinghamshire, UK).

Sequence alignment of homologous SFTSVs

To assess the conservation of each identified epitope among SFTSV homologous proteins, 13 SGn aa sequences from different genetic lineages were obtained from GenBank based on the phylogenetic tree of SFTSV strains [9]. The aa sequences of the SGn segments from the strain WCH/97/HN/China/2011 (GenBank code: AFH88227.1) and other 12 homologous proteins were aligned using the ClustalW program [31] and visualized using Genedoc [32].

Results

Antigenicity identification of the truncated Gn segments

To identify the antigenicity of the truncated Gn and the efficacy of rabbit pAb α-SGn [9], Western blot and immunofluorescence assay (IFA) were carried out. Expressed recombinant SGn (r-SGn) was separated by SDS-PAGE (Fig 2A). The Western blot results showed that r-SGn (29 kDa) had an apparent effect on binding to rabbit pAb α-SGn (Fig 2B). The IFA was conducted to further confirm the reactivity of rabbit pAb α-SGn with the viral particle. The IFA results showed that the rabbit pAb α-SGn reactive with the SFTSV viral particle, but the negative sera were not (Fig 2C). These Western blot and IFA results suggest that r-SGn has efficient antigenicity and pAb α-SGn has an effective ability to recognize antigens.

Fig 2. SDS-PAGE and Western blot analysis of r-SGn expression and identification of reactivity of rabbit pAb α-SGn.

Fig 2

(A) SDS-PAGE analysis of r-SGn expression. M: standard protein marker; BI, total bacterial protein before IPTG induction. (B) Identification of the antigenicity of r-SGn by Western blot using rabbit pAb α-SGn. (C) Identification of the reactivity of pAb α-SGn with the viral particle in Vero cells by IFA; bars indicate 100 μm.

To further identify the antigenicity of truncated overlapping r-SGn, truncated fragments were expressed using the prokaryotic expression vector pET-32a, and each predicted protein was fused with Trx tag, S tag and His tag (with a size about 18 kDa). The SDS-PAGE result showed the expressed recombinant proteins of r-SGn 1 (27 kDa), r-SGn 2 (28 kDa), r-SGn 3(28 kDa), r-SGn 4 (26 kDa), and r-SGn 5 (27 kDa). All recombinant proteins were detected by Western blot analysis using the rabbit α-SGn or anti-His antibody. The result showed that fusion proteins r-SGn1, r-SGn2, and r-SGn3 were reacted with rabbit pAb α-SGn, but not the other fusion expressed proteins (Fig 3). Therefore, we concluded that the region of Gn aa 189–323 contains an epitope that can be recognized by rabbit pAb α-SGn.

Fig 3. Prokaryotic expression and immunoblot analysis of truncated SGn segments.

Fig 3

SDS-PAGE and Western blot analysis of expressed r-SGn1, r-SGn2, r-SGn3, r-SGn4, and r-SGn5 using rabbit pAb α-SGn. BI, total bacterial protein before IPTG induction. The arrows represent the three expressed target segments on the gel and the reactive segments in the Western blot analysis. Samples were loaded on the same gels and were processed in parallel.

Mapping epitopes on the SGn1 and SGn2 segments

To determine the existence of epitopes on the SGn1 and SGn2 segments, the immunodominant region aa 189 to aa 323 of SGn were truncated into 16 16mer peptides using BSPs (P1-P16). The 16 overlapping 16mer peptides were fusion expressed with MBP in E. coli, and the fusion proteins were observed as approximately 42 kDa. Among the 16 expression products, the following six 16mer peptides were identified as positive by Western blot: P1, P6, P9, P12, P13, and P16 (Fig 4A). The sensitivity of the antigen-antibody reaction was determined using the same quantity of peptides for the Western blot detection, and the data were quantitatively analyzed using Image-J software (http://rsb.info.nih.gov/ij/). The relative grayscale results showed that 16mer peptides P1, P6 and P9 had a significantly (P<0.05) higher sensitivity for the antigen-antibody reaction (S1 Fig).

Fig 4. SDS-PAGE and Western blot analysis of MBP fusion proteins expressed 16/8/10mer peptides derived from SGn.

Fig 4

(A) Western blot analysis of expressed 16mer peptides using rabbit pAb α-SGn. (B) Western blot analysis of 42 expressed 8mer peptides and 6 expressed 10mer peptides. BI, total bacterial protein before IPTG induction. NC, negative control (MBP protein expressed by pMAL-c2x). Samples were loaded on the same gels and were processed in parallel. The arrows indicate the 16/8/10mer peptides with a positive antigen-antibody reaction in the Western blot analysis.

To refine and further mapping epitopes on SGn, the positive 16mer peptides were screened in the next round involving 8/10mer peptides. All 48 biosynthetic overlapping 8/10mer peptide aa sequences and corresponding sites on SGn are shown in S2 Table. The Western blot results showed that 8mer peptide P23 (FSQSEFPD) derived from the 16mer peptide P1, was recognized by rabbit pAb α-SGn (Fig 4B). This indicates that the minimal motifs of the epitopes within P1 was 196FSQSEFPD203 (designated epitope, E1), based on the shared residues (Fig 4B). Similarly, other antigenic peptides were further identified and analyzed (Figs 4B and 5). The fine epitopes were 232GHSHKII238 (E2) in P6, 256VCYKEGTGPC265 (E3) in P9, 285FCKVAG290 (E4) in P12 and P13, 316SYGGM320 (E5) in P16.

Fig 5. Synthetic 8/10mer peptide sequences derived from a span of the immunodominant peptides.

Fig 5

The yellow highlighting represents the common sequences among immunodominant peptides that react with rabbit pAb α-SGn according to Western blot analysis.

Cross-reactivity of the identified epitope motifs with anti-SFTSV serum

To determine whether the minimal epitopes are rabbit specific or also recognizable by other host species, five randomly selected 8/10mer peptides, each of which containing one of the five identified BCEs, were subjected to Western blot using sera from sheep with or without SFTSV infection. Results showed that, P23 (containing E1), P25 (containing E2), P62 (containing E3), P44 (containing E4) and P56 (containing E5) were reacted with SFTSV positive sheep sera, while all the epitopes were not reacted with the SFTSV antibody-negative sheep sera (Fig 6).

Fig 6. Western blot of five 8/10mer peptides containing identified epitopes performed using positive sera from sheep with a confirmed history of SFTSV infection.

Fig 6

(A) A positive serum sample from sheep with a confirmed history of SFTSV infection. (B) A serum sample from sheep with no history of SFTSV infection was used as a negative control. NC, negative control (MBP protein expressed by pMAL-c2x). PC, positive control (16mer peptide P1 recognized by sheep positive serum).

3D structures of the minimal motifs of the identified epitopes and sequence conservation analysis

PyMOLTM software was used to simulate the 3D structure of SFTSV-Gn to locate all the mapped epitopes. The results showed that epitopes are located on the surface of the SFTSV-Gn protein (Fig 7). Epitopes E1 (196FSQSEFPD203), E2 (232GHSHKII238), and E5 (316SYGGM320) are located on domain II, E3 (256VCYKEGTGPC265) and E4 (285FCKVAG290) are located on domain III of SFTSV-Gn, all the epitopes were located on a well-defined helix-loop-helix structure (Fig 7A and 7B). The antigenic index and hydrophilicity plot for the SFTSV-Gn aa 189–321 were obtained using the methods of Jameson-Wolf [33] and Kyte-Doolittle [34], respectively. All five epitopes exhibited both high antigenicity and hydrophobicity, this is consistent with the antigenic principles of surface accessibility and hydrophilicity (Fig 7C).

Fig 7. Position of the minimal motifs of the mapped epitopes on the predicted 3D and secondary structure SFTSV-Gn.

Fig 7

The surface (A) and cartoon (B) modeling shows the overall 3D structure of SFTSV-Gn from strain WCH/97/HN/China/2011 (PDB code: 5Y11). The five minimal epitopes are located on the SFTSV-Gn domain II (brown) and III (orange), but not domain I (purple). The molecular surfaces of the five minimal epitopes are shown in different colors (E1, blue; E2, yellow; E3, red; E4, hotpink; E5, paleyellow). The figures were generated using the PyMOLTM molecular graphics system. (C) The antigenic index and hydrophilicity plot prediction for aa residues189-321 of the Gn sequence of SFTSV using DNAStar Protean software. Epitopes were highlighted in blue rectangles.

To assess the conservation of each identified epitope among SFTSV homologous proteins, 13 Gn aa sequences from different countries and genetic lineages were obtained from GenBank based on the phylogenetic tree of SFTSV strains [9]. As far as we know, 13 complete Gn sequences of SFTSV strains isolated in China have been registered in the GenBank database, and these were all compared to the Gn sequence investigated in this study. The aa sequences of the SGn segments from the SFTSV strain WCH/97/HN/China/2011 (GenBank code: AHH92824.1) and other SGn homologous proteins were aligned using the ClustalW program and visualized using Genedoc. The SFTSV strains selected were representative of eight genetic lineages: C1 (China, ADZ04477.1), C2 (China, AOO85597.1; South Korea, AGT98506.1), C3 (China, AHE38391.1), C4 (China, AGI97040.1), C5 (Japan, BAQ59257.1), J1 (Japan, BAQ59263.1; South Korea, APT42346.1), J2 (China, ANC60451.1; Japan, BAQ59261.1) and J3 (Japan, BAN58187.1; China, AMK05828.1). The comparison of the 13 SGn sequences indicated that epitopes E1, E2, E3, E4 and E5 were fully conserved (Fig 8). Therefore, these five epitopes can be used as candidate antigen peptides in SFTSV general diagnostic studies.

Fig 8. Sequence alignment of the homologous SGn segments from SFTSV strains.

Fig 8

The GenBank codes and sources are shown on the left. The five minimal epitopes E1, E2, E3, E4 and E5 recognized by rabbit pAb α-SGn are highlighted in yellow. Dots (.) indicate identical aa residues within all 13 strains.

Discussion

SFTSV is a severe emerging hemorrhagic fever virus that causes thousands of people to be hospitalized each year [2]. No vaccines or effective drugs against SFTSV have yet been developed. Understanding the life cycles of the viral infection may inform the development of important antiviral strategies. The SFTSV glycoprotein Gn/Gc mediates virus entry by binding to cellular receptors and inducing the fusion of the virus to the cell membrane during endocytosis [35]. Gn/Gc may function as an inducer that elicits the production of neutralizing antibodies [16]. Sun and colleagues showed that recombinant SFTSV-Gn bound to susceptible cell lines, Gn might act as a membrane anchoring protein during viral entry into target cells [17, 36].

Classification by protein topology, SFTSV-Gn was a type I transmembrane protein [37] that contained the N-terminal ectodomain dominated the cell surface binding capability. The SFTSV-Gn structure can be divided into the head and stem domains, the head domain corresponds to Gn 20–337, and the stem domain corresponds to Gn 338–452. The stem domain was responsible for the dimerization of SFTSV-Gn via disulfide bonds [23, 38]. However, the structure of the Gn stem domain remains unknown. Gn was also the target for neutralization antibodies, indicates that it is an important protein for prevention and vaccine design, as well as the study of viral infection mechanism of SFTSV. Recently, Wu et al. [23] reported the crystal structures of Gn head domains from SFTSV, and indicated that SFTSV-Gn can be reacted with mAb 4–5, a neutralizing monoclonal single chain fragment variable (ScFv) antibody cloned from SFTS recovered patient [22]. The structure of the Gn head domain, which was composed of three subdomains including domain I, II and III. MAb 4–5 binds to domain III of SFTSV-Gn. The neutralizing effect of mAb4-5 has been shown only in vitro. However, it’s in vivo efficacy remains to be investigated. Kim et al. [21] reported that mAb 10 binding to Gn was predicted to be affected by domain II and the stem region of SFTSV-Gn. Unlike the mAb4-5, the mAb10 showed a potent neutralizing effect in vitro and protective effect in vivo.

In the present study, we applied the modified BSP method to identify the immunodominant BCEs in the SGn from SFTSV. The SFTSV strain WCH/97/HN/China/2011 was selected for fine epitopes mapping. Several outstanding merits of BSP/MBP method are summarized as follows: i) using the truncated MBP as a carrier, it makes the expressed 16/8/10mer peptides fusion proteins in the weak antigenic area of bacterial proteins, and thus permits using them to map the BCEs of target protein; ii) it is simple, cost-effective and cheaper compared with other epitope mapping methods [24, 25]. Five linear epitopes were identified using rabbit pAb α-SGn. The epitopes comprised are listed as E1 (196FSQSEFPD203), E2 (232GHSHKII238), and E5 (316SYGGM320) on domain II, E3 (256VCYKEGTGPC265) and E4 (285FCKVAG290) on domain III of SFTSV-Gn. As described above, mAb4-5 and mAb 10 bind to domain III and II, respectively, indicating that these subdomains were highly antigenic regions on the SFTSV-Gn. It is worth noting that, the epitopes recognized by mAb 4–5 or mAb 10 were conformational and not linear to the paratope [21, 23].

The sequences of 13 strains of SFTSV from different countries and lineages were being analyzed. The results showed that five epitopes (E1, E2, E3, E4 and E5) were fully conserved among the 13 SFTSV strains (Fig 8). Therefore, these five BCEs can be used as a selectable candidate for general diagnostic studies. The SFTSV-Gn 3D structure and the distribution of the five epitope motifs of SGn were analyzed using PyMOLTM software. The results showed that five epitopes were exposed on the surface of the 3D structure, contained in the flexible helix-loop-helix region (Fig 7), indicating that they could easily bind to the antibodies. The epitopes located on the surface of the target protein play an important role in the future development of drugs that interact with target antigens. It is generally believed that the multi-epitope based recombinant vaccines offer numerous advantages compared to the protein-based vaccine. These advantages are including multi-valency cost- effectiveness, economical production and stability under different ambient conditions. Moreover, the efficacy of multi-epitope vaccines can be further improved by combining helper T cells and promiscuous epitopes, and adopting toll-like receptor ligands as an adjuvant [39, 40]. However, we have not yet known that the identified five BCEs of SGn in this study will obtain the neutralizing activity. Further study in this direction is needed for verification.

In conclusion, the five high conserved linear BCEs (E1, E2, E3, E4 and E5) were recognized with rabbit pAb α-SGn. All the five epitopes interacted with the sheep serum infected naturally with SFTSV. Our results will escalate the understanding of the epitope distribution and function of SFTSV-Gn, and provide fundamental information for the elucidation of the design and development of a SFTSV multi-epitope peptide detection antigen.

Supporting information

S1 Table. 16mer peptides amino acid sequence and its location on SFTSV-Gn.

(DOC)

S2 Table. 8/10mer peptides amino acid sequence and its location on SFTSV-Gn.

(DOC)

S1 Fig. Relative grayscale level analyses of 16/8/10mer peptides from Western blot using Image-J software.

To determine the sensitivity of the antigen-antibody reaction involving the 16mer (A) and 8/10mer (B) peptides, quantitative analyses were performed using the same quantity of peptides for detection. The relative grayscale level of each 16/8/10mer peptide compared to the positive 16mer peptide P1 was analyzed according to the results in Fig 3. Statistical analysis of data was performed using one-way analysis of variance (ANOVA) to determine the significant differences using SPSS software. Letters (a, b, c) indicate the significant differences (P<0.05).

(TIF)

S1 Raw images

(PDF)

Data Availability

All relevant data are within the paper and its Supporting Information files

Funding Statement

This work was supported partly by grants from the National Natural Science Foundation of China (No. 81760365, 81690369 to S. R. S.), the Science Research Key Project of Xinjiang Education Department (No. XJEDU2019I002 to S. R. S.), and the Science and Technology Basic Work Program (No. 2013FY113500 to Y. J. Z) from the Ministry of Science and Technology of China, and funded by the Open Research Fund Program of the State Key Laboratory of Virology of China (No. 2015IOV003 to F. D.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011. April 21; 364 (16): 1523–32. 10.1056/NEJMoa1010095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Chen YX, Jia B, Liu Y, Huang R, Chen JH, Wu C. Risk factors associated with fatality of severe fever with thrombocytopenia syndrome: a meta-analysis. Oncotarget. 2017; 8(51): 89119–89129. 10.18632/oncotarget.19163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Liu Q, He B, Huang SY, Wei F, Zhu XQ. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis. 2014; 14(8): 763–772. 10.1016/S1473-3099(14)70718-2 [DOI] [PubMed] [Google Scholar]
  • 4.Kim KH, Yi JY, Kim G, Choi SJ, Jun KI, Kim NH, et al. Severe fever with thrombocytopenia syndrome, South Korea, 2012. Emerg Infect Dis. 2013; 19(11): 1892–1894. 10.3201/eid1911.130792 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T, et al. The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis. 2014; 209(6): 816–827. 10.1093/infdis/jit603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Yoshikawa T, Shimojima M, Fukushi S, Tani H, Fukuma A, Taniguchi S, et al. Phylogenetic and geographic relationships of severe fever with thrombocytopenia syndrome virus in China, South Korea, and Japan. J Infect Dis. 2015; 212(6): 889–898. 10.1093/infdis/jiv144 [DOI] [PubMed] [Google Scholar]
  • 7.Lei XY, Liu MM, Yu XJ. Severe fever with thrombocytopenia syndrome and its pathogen SFTSV. Microbes Infect. 2015; 17(2): 149–154. 10.1016/j.micinf.2014.12.002 [DOI] [PubMed] [Google Scholar]
  • 8.Park SW, Song BG, Shin EH, Yun SM, Han MG, Park MY, et al. Prevalence of severe fever with thrombocytopenia syndrome virus in Haemaphysalis longicornis ticks in South Korea. Ticks Tick Borne Dis. 2014; 5(6): 975–977. 10.1016/j.ttbdis.2014.07.020 [DOI] [PubMed] [Google Scholar]
  • 9.Shen S, Duan XM, Wang B, Zhu LY, Zhang YF, Zhang JY, et al. A novel tick-borne phlebovirus, closely related to severe fever with thrombocytopenia syndrome virus and Heartland virus, is a potential pathogen. Emerg Microbes Infect. 2018; 7(1): 95. 10.1038/s41426-018-0093-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Niu G, Li JD, Liang MF, Jiang XL, Jiang M, Yin HY, et al. Severe fever with thrombocytopenia syndrome virus among domesticated animals, China. Emerg Infect Dis. 2013; 19(5): 756–763. 10.3201/eid1905.120245 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Tian HY, Yu PB, Chowell G, Li S, Wei J, Tian H, et al. Severe fever with thrombocytopenia syndrome virus in Humans, Domesticated Animals, Ticks, and Mosquitoes, Shaanxi Province, China. Am J Trop Med Hyg. 2017; 96(6): 1346–1349. 10.4269/ajtmh.16-0333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Park ES, Shimojima M, Nagata N, Ami Y, Yoshikawa T, Iwata-Yoshikawa N, et al. Severe fever with thrombocytopenia syndrome Phlebovirus causes lethal viral hemorrhagic fever in cats. Sci Rep. 2019. August 19; 9(1): 11990. 10.1038/s41598-019-48317-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Liu Y, Li Q, Hu WF, Wu JB, Wang YB, Mei L, et al. Person-to-person transmission of severe fever with thrombocytopenia syndrome virus. Vector Borne Zoonotic Dis. 2012; 12(2): 156–160. 10.1089/vbz.2011.0758 [DOI] [PubMed] [Google Scholar]
  • 14.Kuhn JH, Adkins S, Alioto D, Alkhovsky SV, Amarasinghe GK, Anthony SJ, et al. 2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Arch Virol. 2020. December;165 (12): 3023–3072. 10.1007/s00705-020-04731-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tani H, Shimojima M, Fukushi S, Yoshikawa T, Fukuma A, Taniguchi S, et al. Characterization of glycoprotein-mediated entry of severe fever with thrombocytopenia syndrome virus. J Virol. 2016. May 12; 90(11): 5292–5301. 10.1128/JVI.00110-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hofmann H, Li X, Zhang X, Liu W, Kühl A, Kaup F, et al. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. J Virol. 2013. April; 87(8): 4384–4394. 10.1128/JVI.02628-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Spiegel M, Plegge T, Pöhlmann S. The Role of Phlebovirus glycoproteins in viral entry, essembly and release. Viruses. 2016; 8(7): 202. 10.3390/v8070202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Gerrard SR, Nichol ST. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the rift valley fever virus glycoproteins. Virology. 2007; 357(2): 124–133. 10.1016/j.virol.2006.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cifuentes-Muñoz N, Salazar-Quiroz N, Tischler ND. Hantavirus Gn and Gc envelope glycoproteins: key structural units for virus cell entry and virus assembly. Viruses. 2014; 6(4): 1801–1822. 10.3390/v6041801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Yuan F, Zheng AH. Entry of severe fever with thrombocytopenia syndrome virus. Virol Sin. 2017; 32(1): 44–50. 10.1007/s12250-016-3858-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kim KH, Kim J, Ko M, Chun JY, Kim H, Kim S, et al. An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus. PLoS Pathog. 2019; 15(2): e1007375. 10.1371/journal.ppat.1007375 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Guo XL, Zhang L, Zhang WS, Chi Y, Zeng XY, Li X, et al. Human antibody neutralizes severe fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus. Clin Vaccine Immunol. 2013; 20(9):1426–1432. 10.1128/CVI.00222-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wu Y, Zhu YH, Gao F, Jiao YJ, Oladejo BO, Chai Y, et al. Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope. Proc Natl Acad Sci U S A. 2017; 114(36): E7564–E7573. 10.1073/pnas.1705176114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Xu WX, He YP, Tang HP, Jia XF, Ji CN, Gu SH, et al. Minimal motif mapping of a known epitope on human zona pellucida protein-4 using a peptide biosynthesis strategy. J Reprod Immunol. 2009; 81(1):9–16. 10.1016/j.jri.2009.04.004 [DOI] [PubMed] [Google Scholar]
  • 25.Xu WX, Wang J, Tang HP, Chen LH, Lian WB, Zhan JM, et al. A simpler and more cost-effective peptide biosynthetic method using the truncated GST as carrier for epitope mapping. PLoS One. 2017; 12(10): e0186097. 10.1371/journal.pone.0186097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Yu RS, Fan XM, Xu WX, Li WT, Dong SJ, Zhu YM, et al. Fine mapping and conservation analysis of linear B-cell epitopes of peste des petits ruminants virus nucleoprotein. Vet Microbiol. 2015; 175(1): 132–138. 10.1016/j.vetmic.2014.10.012 [DOI] [PubMed] [Google Scholar]
  • 27.Moming A, Zhang YJ, Chang CC, Yu H, Wang MF, Hu Z, et al. Antigenicity of severe fever with thrombocytopenia syndrome virus nucleocapsid protein and its potential application in the virus serodiagnosis. Virol Sin. 2017. February; 32(1): 97–100. 10.1007/s12250-016-3928-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Mahmoodi P, Shapouri MR, Ghorbanpour M, Ekhtelat M, Hajikolaei MR, Lotfi M, et al. Epitope mapping of bovine viral diarrhea virus nonstructural protein 3. Vet Immunol Immunopathol. 2014; 161(3–4): 232–239. 10.1016/j.vetimm.2014.08.012 [DOI] [PubMed] [Google Scholar]
  • 29.Kang QZ, Duan GC, Fan QT, Xi YL. Fusion expression of Helicobacter pylori neutrophil-activating protein in E.coli. World J Gastroenterol. 2005; 11(3): 454–456. 10.3748/wjg.v11.i3.454 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979; 76(9):4350–4354. 10.1073/pnas.76.9.4350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003; 31(13): 3497–3500. 10.1093/nar/gkg500 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Piast M, Kustrzeba-Wójcicka I, Matusiewicz M, Banaś T. Molecular evolution of enolase. Acta Biochim Pol. 2005; 52(2): 507–513 [PubMed] [Google Scholar]
  • 33.Jameson BA, Wolf H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci. 1988; 4(1): 181–186. 10.1093/bioinformatics/4.1.181 [DOI] [PubMed] [Google Scholar]
  • 34.Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982; 157(1): 105–132. 10.1016/0022-2836(82)90515-0 [DOI] [PubMed] [Google Scholar]
  • 35.Hofmann H, Li XX, Zhang XA, Liu W, Kühl A, Kaup F, et al. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. J Virol. 2013; 87(8): 4384–4394. 10.1128/JVI.02628-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Sun YY, Qi YH, Liu CX, Gao WQ, Chen P, Fu LR, et al. Nonmuscle myosin heavy chain IIA is a critical factor contributing to the efficiency of early infection of severe fever with thrombocytopenia syndrome virus. J Virol. 2014; 88(1): 237–248. 10.1128/JVI.02141-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Podbilewicz B. Virus and cell fusion mechanisms. Annu Rev Cell Dev Biol. 2014; 30: 111–139. 10.1146/annurev-cellbio-101512-122422 [DOI] [PubMed] [Google Scholar]
  • 38.Plegge T, Hofmann-Winkler H, Spiegel M, Pöhlmann S. Evidence that processing of the severe fever with thrombocytopenia syndrome virus Gn/Gc polyprotein is critical for viral infectivity and requires an internal Gc signal peptide. PLoS One. 2016; 11(11): e0166013. 10.1371/journal.pone.0166013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Rosa DS, Ribeiro SP, Fonseca SG, Almeida RR, Santana VC, Apostólico Jde S, et al. Multiple Approaches for increasing the immunogenicity of an epitope-based anti-HIV vaccine. AIDS Res Hum Retroviruses. 2015; 31(11): 1077–1088. 10.1089/AID.2015.0101 [DOI] [PubMed] [Google Scholar]
  • 40.Nezafat N, Ghasemi Y, Javadi G, Khoshnoud MJ, Omidinia E. A novel multi-epitope peptide vaccine against cancer: an in silico approach. J Theor Biol. 2014; 349: 121–134. 10.1016/j.jtbi.2014.01.018 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Paulo Lee Ho

23 Dec 2020

PONE-D-20-32530

Fine mapping epitope on Glycoprotein-Gn from Severe Fever with Thrombocytopenia Syndrome Virus

PLOS ONE

Dear Dr. Sun,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

1) Please provide more details of the antiserum used to map the Severe Fever with Thrombocytopenia Syndrome Vírus Glycoprotein. How was it generated? What is it specificity? Was is purified? How?

2) The authors did not show that the linear epitopes are protective or induce neutralizing antibodies against the vírus. Modify the discussion accordingly;

3) Please, see the comments raised by both the reviewers.

Please submit your revised manuscript by Feb 06 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Paulo Lee Ho, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Methods section, please specify the source of the serum samples from the healthy rabbit and healthy sheep used for your study.

3.We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

  • The name of the colleague or the details of the professional service that edited your manuscript

  • A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

  • A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

4. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

5. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Moming A et al. have mapped the epitopes on glycoprotein Gn of SFTSV. The study is interesting and the work was done very carefully and very well. There are few mistakes need to be changed in the manuscript.

1. Throughout the manuscript Western should be capitalized for Western blot.

2. The following method description in the result section should be deleted.

1) Between lines 221 and 224, “Expressed recombinant SGn (r-SGn) was first separated by SDS-PAGE (Fig 2A) and then transferred to nitrocellulose membranes; pAb α-SGn (1:1000 dilution) was used as the primary antibody, and HRP-conjugated goat anti-rabbit IgG (1:5000 dilution) was used as the secondary antibody”.

2) Between lines 257 and 259, “NC membranes were blocked with 5% (w/v) skimmed milk powder, incubated sequentially with rabbit pAb α-SGn (1:1000 dilution), and incubated with goat anti-rabbit (1:5000 dilution), and then visualized by ECL”.

3) Between lines 277 and 279, “NC membranes were blocked with 5% (w/v) skimmed milk powder, incubated sequentially with rabbit pAb α-SGn (1:1000 dilution) and goat anti-rabbit IgG (1:5000 dilution), and then visualized by ECL”.

3. Missing references:

1) Online 59, a reference (Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364(16):1523-1532) should be added.

2) On line 65, SFTSV is not Banyangvirus. You need change the name of the virus to Bandavirus and use the reference “Kuhn JH, Adkins S, Alioto D, et al. 2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Arch Virol. 2020;165:3023-3072” to replace reference 12.

3) Online 65, you need add references for the statement “Studies have indicated that GP mediate the first step in the virus replication cycle viral entry, and are the only targets for neutralizing antibodies”

Reviewer #2: The manuscript entitles “Fine mapping epitope on Glycoprotein-Gn from Severe Fever with Thrombocytopenia Syndrome Virus” describes the linear epitope mapping of Gn protein of SFTS virus. The authors showed the five linear epitopes in the Sn protein, 196-203, 232-238, 256-265, 285-290, and 316-320 amino acid residues, respectively. The epitopes were mapped using rabbit anti Sgn antibody and the epitopes were also recognized by SFTS antibody-positive sheep sera. The manuscript is well written and the methods to map the epitopes were appropriate. However, there are two major criticism as written in the “Major points”.

Major points:

The epitopes were mapped using rabbit pAb a-SGn (reference No8) supplied from Prof. Deng, however in the reference manuscript any detail of the rabbit a-SGn was written. Thus, the authors should describe the detail of the antibody as to how the rabbit serum was prepared, whether the antibody has viral neutralizing antibody against SFTSV.

From the data shown in the manuscript, it is too much to discuss “these linear epitopes identified in the manuscript provide fundamental data for the elucidation of the design and development of a SFTSV multi-epitope peptide vaccine”, since the authors never showed the antibodies to these linear epitopes have viral neutralizing capacity of not. Actual;ly, the authors describe “However, whether the identified five BCEs of SGn in this study have neutralizing activity require further verification (line 395-396). The reviewer agrees that the data shown in the manuscript provide useful data for the development of a novel SFTS antibody detection antigen. Thus, the authors are recommended to remove the sentence describing vaccine development.

Minor points;

Line 62: “including goats, cattle, dogs, and chickens [8-10]” lacks cats as susceptible animal. Scientific Reports, 19(1): 11990 (2019) showed that cats were susceptible for SFTSV and the virus caused lethal infection in cats. The authors should add this manuscript to the reference.

Line 110: “involving” should be “involve”

Line 142-143: “computer controlled microscope” should be changed to “ the name of microscope product name”

Line 143: “Olympics” is “Olympus” ??

Line 269: “ … MBP fusion expressed …” should be “… MBP fusion proteins expressed …

Line 364 -365: “mAb 4-5, a neutralizing antibody identified in SFTS recovered patients” is not precise. mAb 4-5, a neutralizing monoclonal ScFv antibody cloned from SFTS recovered patient.”

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 2;16(3):e0248005. doi: 10.1371/journal.pone.0248005.r002

Author response to Decision Letter 0


12 Jan 2021

Reviewer #1: Moming A et al. have mapped the epitopes on glycoprotein Gn of SFTSV. The study is interesting and the work was done very carefully and very well. There are few mistakes need to be changed in the manuscript.

1. Throughout the manuscript Western should be capitalized for Western blot.

Response: Thanks for the good remind. We have revised Western to capitalized Western blot in the manuscript.

2. The following method description in the result section should be deleted.

1) Between lines 221 and 224, “Expressed recombinant SGn (r-SGn) was first separated by SDS-PAGE (Fig 2A) and then transferred to nitrocellulose membranes; pAb α-SGn (1:1000 dilution) was used as the primary antibody, and HRP-conjugated goat anti-rabbit IgG (1:5000 dilution) was used as the secondary antibody”.

2) Between lines 257 and 259, “NC membranes were blocked with 5% (w/v) skimmed milk powder, incubated sequentially with rabbit pAb α-SGn (1:1000 dilution), and incubated with goat anti-rabbit (1:5000 dilution), and then visualized by ECL”.

3) Between lines 277 and 279, “NC membranes were blocked with 5% (w/v) skimmed milk powder, incubated sequentially with rabbit pAb α-SGn (1:1000 dilution) and goat anti-rabbit IgG (1:5000 dilution), and then visualized by ECL”.

Response: Thanks for the kind suggestion. We have deleted the above method description in the result section in the revised manuscript.

3. Missing references:

1) Online 59, a reference (Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364(16):1523-1532) should be added.

Response: Thanks for the valuable suggestion. We have added this reference in line 37.

.

2) On line 65, SFTSV is not Banyangvirus. You need change the name of the virus to Bandavirus and use the reference “Kuhn JH, Adkins S, Alioto D, et al. 2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Arch Virol. 2020;165:3023-3072” to replace reference 12.

Response: Thanks for the good remind. We apologize for this oversight, the classification of SFTSV was updated according to reference (14) as Bandavirus genus within the family Phenuiviridae. Reference [12] has been replaced as [14] in the revised version in line 44.

[14] Kuhn JH, Adkins S, Alioto D, Alkhovsky SV, Amarasinghe GK, Anthony SJ, et al. 2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Arch Virol. 2020 Dec;165 (12): 3023-3072. https://doi: 10.1007/s00705-020-04731-2 PMID: 32888050

3) On line 65, you need add references for the statement “Studies have indicated that GP mediate the first step in the virus replication cycle viral entry, and are the only targets for neutralizing antibodies”.

Response: Thanks for the good remind. We apologize for our earlier lack of clarity. We have added references [15] and [16] in line 48 of the revised manuscript.

[15] Tani H, Shimojima M, Fukushi S, Yoshikawa T, Fukuma A, Taniguchi S, et al. Characterization of glycoprotein-mediated entry of severe fever with thrombocytopenia syndrome virus. J Virol. 2016 May 12; 90(11): 5292-5301. https://doi: 10.1128/JVI.00110-16 PMID: 26984731

[16] Hofmann H, Li X, Zhang X, Liu W, Kühl A, Kaup F, et al. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. J Virol. 2013 Apr; 87(8): 4384-4394. https://doi: 10.1128/JVI.02628-12 PMID: 23388721

Reviewer #2: The manuscript entitles “Fine mapping epitope on Glycoprotein-Gn from Severe Fever with Thrombocytopenia Syndrome Virus” describes the linear epitope mapping of Gn protein of SFTS virus. The authors showed the five linear epitopes in the Sn protein, 196-203, 232-238, 256-265, 285-290, and 316-320 amino acid residues, respectively. The epitopes were mapped using rabbit anti Sgn antibody and the epitopes were also recognized by SFTS antibody-positive sheep sera. The manuscript is well written and the methods to map the epitopes were appropriate. However, there are two major criticism as written in the “Major points”.

Major points:

The epitopes were mapped using rabbit pAb a-SGn (reference No8) supplied from Prof. Deng, however in the reference manuscript any detail of the rabbit a-SGn was written. Thus, the authors should describe the detail of the antibody as to how the rabbit serum was prepared, whether the antibody has viral neutralizing antibody against SFTSV.

Response: Thanks for the good remind. We have provided information on antiserum used to map the Severe Fever with Thrombocytopenia Syndrome Vírus Glycoprotein Gn in the materials and methods section in line 94-102. The main preparation methods are as follows:The coding region (aa, 189-451) of SFTSV-Gn from strain WCH/97/HN/China/2011 was amplified by PCR using 2×Rapid Taq Master Mix (Vazyme Biotech, Nanjing, China) according to the manufacture’s instruction. The PCR products were cloned into the plasmid pET-28a to generate the expression plasmid pET-28a-SGn and the insert was confirmed by sequencing. Protein expression and purification were conducted as described [27]. New Zealand rabbits were injected intramuscularly with 0.5 mg of purified SGn segment and immunized at two-week intervals according to the conventional animal immune method. After the third immunization for two weeks, rabbit antiserum was separated and stored at -80℃ until use. The neutralizing activity of rabbit pAb α-SGn against SFTSV was detected using IFA, but no neutralizing effect was found.

[27] Moming A, Zhang YJ, Chang CC, Yu H, Wang MF, Hu Z, et al. Antigenicity of severe fever with thrombocytopenia syndrome virus nucleocapsid protein and its potential application in the virus serodiagnosis. Virol Sin. 2017 Feb; 32(1): 97-100. https://doi: 10.1007/s12250-016-3928-9 PMID: 28120219

From the data shown in the manuscript, it is too much to discuss “these linear epitopes identified in the manuscript provide fundamental data for the elucidation of the design and development of a SFTSV multi-epitope peptide vaccine”, since the authors never showed the antibodies to these linear epitopes have viral neutralizing capacity of not. Actually, the authors describe “However, whether the identified five BCEs of SGn in this study have neutralizing activity require further verification (line 395-396). The reviewer agrees that the data shown in the manuscript provide useful data for the development of a novel SFTS antibody detection antigen. Thus, the authors are recommended to remove the sentence describing vaccine development.

Response: Thanks for the good suggestion. We have removed the sentence describing vaccine development in the revised manuscript.

Minor points;

Line 62: “including goats, cattle, dogs, and chickens [8-10]” lacks cats as susceptible animal. Scientific Reports, 19(1): 11990 (2019) showed that cats were susceptible for SFTSV and the virus caused lethal infection in cats. The authors should add this manuscript to the reference.

Response: Thanks for the kind remind and suggestion. We have added cats as susceptible animal for SFTSV, and added as reference [12] in line 40 in the revised manuscript.

[12] Park ES, Shimojima M, Nagata N, Ami Y, Yoshikawa T, Iwata-Yoshikawa N, et al. Severe fever with thrombocytopenia syndrome Phlebovirus causes lethal viral hemorrhagic fever in cats. Sci Rep. 2019 Aug 19; 9(1): 11990. https://doi: 10.1038/s41598-019-48317-8 PMID: 31427690

Line 110: “involving” should be “involve”

Response: Thanks for the good remind. “involving” was revised as “involve” in line 90.

Line 142-143: “computer controlled microscope” should be changed to “ the name of microscope product name”

Response: Thanks for the kind remind. “computer controlled microscope” was changed as “IX73 microscope” in lines 129.

Line 143: “Olympics” is “Olympus” ??

Response: Thanks for the good remind. “Olympics” was revised as “Olympus” in line 129.

Line 269: “ … MBP fusion expressed …” should be “… MBP fusion proteins expressed …

Response: Thanks for the good remind. “MBP fusion expressed” was revised as “MBP fusion proteins expressed” in line 250.

Line 364 -365: “mAb 4-5, a neutralizing antibody identified in SFTS recovered patients” is not precise. mAb 4-5, a neutralizing monoclonal ScFv antibody cloned from SFTS recovered patient.”

Response: Thanks for the good remind. “mAb 4-5, a neutralizing antibody identified in SFTS recovered patients” was revised as “mAb 4-5, a neutralizing monoclonal single chain fragment variable (ScFv) antibody cloned from SFTS recovered patient” in lines 342-343.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Paulo Lee Ho

9 Feb 2021

PONE-D-20-32530R1

Fine mapping epitope on Glycoprotein-Gn from Severe Fever with Thrombocytopenia Syndrome Virus

PLOS ONE

Dear Dr. Sun,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 26 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Paulo Lee Ho, Ph.D.

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The minor comments are on line 178 bacteria culture should be bacterial culture and on line 242 E. coli should be italicized.

Reviewer #2: In the revised manuscript, all the comments have been properly addressed, thus the manuscript is considered to be accepted.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Xue-jie Yu

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 2;16(3):e0248005. doi: 10.1371/journal.pone.0248005.r004

Author response to Decision Letter 1


10 Feb 2021

Reviewer #1: The minor comments are on line 178 bacteria culture should be bacterial culture and on line 242 E. coli should be italicized.

Response: Thanks for the good remind. We apologize for our carelessness, we have revised “bacteria culture” as “bacterial culture” on line 178, and italicized E. coli on line 242 in the manuscript.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Paulo Lee Ho

18 Feb 2021

Fine mapping epitope on Glycoprotein-Gn from Severe Fever with Thrombocytopenia Syndrome Virus

PONE-D-20-32530R2

Dear Dr. Sun,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Paulo Lee Ho, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Paulo Lee Ho

22 Feb 2021

PONE-D-20-32530R2

Fine mapping epitope on Glycoprotein-Gn from Severe Fever with Thrombocytopenia Syndrome Virus

Dear Dr. Sun:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Paulo Lee Ho

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. 16mer peptides amino acid sequence and its location on SFTSV-Gn.

    (DOC)

    S2 Table. 8/10mer peptides amino acid sequence and its location on SFTSV-Gn.

    (DOC)

    S1 Fig. Relative grayscale level analyses of 16/8/10mer peptides from Western blot using Image-J software.

    To determine the sensitivity of the antigen-antibody reaction involving the 16mer (A) and 8/10mer (B) peptides, quantitative analyses were performed using the same quantity of peptides for detection. The relative grayscale level of each 16/8/10mer peptide compared to the positive 16mer peptide P1 was analyzed according to the results in Fig 3. Statistical analysis of data was performed using one-way analysis of variance (ANOVA) to determine the significant differences using SPSS software. Letters (a, b, c) indicate the significant differences (P<0.05).

    (TIF)

    S1 Raw images

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES